Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Director | June 30, 2021 | July 01, 2021 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 07, 2026 | January 08, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | September 30, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kaleido Biosciences, Inc.
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29 | Direct | 15,000 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000 |
REGENERON PHARMACEUTICALS, INC.
Report date January 07, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,703 |
Ending reported balance
After 2026-01-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-07 · Exercise / conversion · Acquired 1,500 · Balance 3,203 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. Row 2 · 2026-01-07 · Sale · Disposed 1,500 · Balance 1,703 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. F2: Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $374.12 · Expires 2030-01-02 | Direct | 2,861 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Exercise / conversion · Disposed 1,500 · Balance 2,861 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. F3: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025.
F2: Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price.
F3: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
Royalty Pharma plc
Report date September 30, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 79,823 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 642 · Balance 79,823 F1: Reflects Class A Ordinary Shares issued to the Reporting Person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Class A Ordinary Shares issued to the Reporting Person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cidara Therapeutics, Inc.
Report date January 07, 2026 · Filed January 08, 2026
Section 16 reporting ended · disclosed 2026-01-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Disposition to issuer · Disposed 15 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes. F4: The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.20 · Expires 2031-01-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Disposition to issuer · Disposed 1,750 · Balance 0 F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 · Expires 2031-06-22 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Disposition to issuer · Disposed 875 · Balance 0 F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2032-06-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-07 · Disposition to issuer · Disposed 1,400 · Balance 0 F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.40 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-07 · Disposition to issuer · Disposed 2,125 · Balance 0 F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2034-07-17 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-07 · Disposition to issuer · Disposed 2,125 · Balance 0 F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.81 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-07 · Disposition to issuer · Disposed 16,000 · Balance 0 F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.31 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-07 · Disposition to issuer · Disposed 11,100 · Balance 0 F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2]
F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]
F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes.
F4: The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2024 Filed Jan 31, 2024 21:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001883850-24-000010 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 827 Underlying: Common Stock · 827 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 827 | $959.00 | $793,093.00 |
DisclosureSEC source: 0001883850-24-000010 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:52 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 827 | $380.95 | $315,045.65 |
DisclosureSEC source: 0001883850-24-000010 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 826 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001968202-24-000027 · edgardoc.xml · derivative · entry 4 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,654 Underlying: Common Stock · 826 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 826 | $914.00 | $754,964.00 |
DisclosureSEC source: 0001968202-24-000027 · edgardoc.xml · nonDerivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 826 | $380.95 | $314,664.70 |
DisclosureSEC source: 0001968202-24-000027 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001968202-24-000027 · edgardoc.xml · derivative · entry 5 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 1,607 shares Expires 2034-01-02 F4 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000027 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 22:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,353 | $27.71 | $37,492.98 |
DisclosureSEC source: 0001802768-23-000035 · wk-form4_1703887896.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,522 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 610 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001883850-23-000099 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 610 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 610 | $870.00 | $530,700.00 |
DisclosureSEC source: 0001883850-23-000099 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 610 | $376.69 | $229,780.90 |
DisclosureSEC source: 0001883850-23-000099 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:23 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,384 | $27.08 | $37,475.26 |
DisclosureSEC source: 0001209191-23-051471 · doc4.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,169 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 853 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001968202-23-000022 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 854 Underlying: Common Stock · 853 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 853 | $829.00 | $707,137.00 |
DisclosureSEC source: 0001968202-23-000022 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 853 | $391.92 | $334,307.76 |
DisclosureSEC source: 0001968202-23-000022 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 853 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001883850-23-000077 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,707 Underlying: Common Stock · 853 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 853 | $789.00 | $673,017.00 |
DisclosureSEC source: 0001883850-23-000077 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 853 | $391.92 | $334,307.76 |
DisclosureSEC source: 0001883850-23-000077 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 13:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,208 | $31.03 | $37,480.98 |
DisclosureSEC source: 0001209191-23-040237 · doc4.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,785 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:02 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 7,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039671 · doc4.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,577 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 21:17 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001610618-23-000063 · wf-form4_168755504603545.xml · derivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2024 annual meeting of stockholders. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 20:38 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,049 | $35.73 | $37,478.25 |
DisclosureSEC source: 0001209191-23-021880 · doc4.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,830 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,240 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001883850-23-000064 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,480 Underlying: Common Stock · 1,240 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,240 | $818.00 | $1,014,320.00 |
DisclosureSEC source: 0001883850-23-000064 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:43 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,240 | $380.95 | $472,378.00 |
DisclosureSEC source: 0001883850-23-000064 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,021 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001883850-23-000036 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,720 Underlying: Common Stock · 1,021 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,021 | $779.00 | $795,359.00 |
DisclosureSEC source: 0001883850-23-000036 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,021 | $380.95 | $388,949.95 |
DisclosureSEC source: 0001883850-23-000036 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,929 | $0.00 Strike: $725.89 | $0.00 |
DisclosureSEC source: 0001883850-23-000020 · edgardoc.xml · derivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Underlying: Common Stock · 1,929 shares Expires 2033-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 165 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000020 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 22:09 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 943 | $39.76 | $37,494.91 |
DisclosureSEC source: 0001209191-23-000322 · doc4.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,781 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 218 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001883850-22-000108 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,741 Underlying: Common Stock · 218 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 218 | $779.00 | $169,822.00 |
DisclosureSEC source: 0001883850-22-000108 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 218 | $380.95 | $83,047.10 |
DisclosureSEC source: 0001883850-22-000108 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 30, 2022 Filed Sep 30, 2022 20:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 913 | $41.06 | $37,490.43 |
DisclosureSEC source: 0001209191-22-051644 · doc4.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,838 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 609 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · derivative · entry 7 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610 Underlying: Common Stock · 609 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 609 | $741.00 | $451,269.00 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · nonDerivative · entry 6 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 609 | $376.69 | $229,404.21 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · nonDerivative · entry 5 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,279 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · derivative · entry 9 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,560 Underlying: Common Stock · 1,279 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,279 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · derivative · entry 8 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,839 Underlying: Common Stock · 1,279 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,279 | $686.99 | $878,660.21 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · nonDerivative · entry 4 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,279 | $391.92 | $501,265.68 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · nonDerivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,279 | $705.00 | $901,695.00 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 1,279 shares of Company stock on September 8, 2022 at prices ranging from $705.00 to $705.06. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 8, 2022 at each separate price. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,279 | $391.92 | $501,265.68 |
DisclosureSEC source: 0001883850-22-000068 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 30, 2022 Filed Jun 30, 2022 10:55 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 903 | $41.52 | $37,492.83 |
DisclosureSEC source: 0001209191-22-039877 · doc4.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,925 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 24, 2022 Filed Jun 24, 2022 20:57 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 6,328 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-024042 · doc4.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,022 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:31 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001610618-22-000056 · wf-form4_165610629103916.xml · derivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:38 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,240 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-22-000038 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,959 Underlying: Common Stock · 1,240 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:38 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,240 | $725.00 | $899,000.00 |
DisclosureSEC source: 0001708138-22-000038 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.